Description
Indications
Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.
How It Works
TRK ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3
Pharmacology
12.1 How It Works (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3
Dosage
2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:
Precautions
5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)
Drug Interactions
7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dosage(2.5)] CYP3A4 ， ， [ Dosage(2.5)]
Adverse Reactions
Description [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] 6.1 ， ， ， Precautions 444 VITRAKVI ， 62% 6 ，44% ……
Storage
25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F
